Our study suggests that a better approach to treatment could be targeting the specific T cell subsets that are harmful or beneficial in IPF, for example, augmenting CCR4+ CD4+ T cell recruitment to the lungs while blocking CCR6+ CD4+ T cells. Here, CCR4 is linked to idiopathic pulmonary fibrosis.